Pfizer announced that the Japanese Ministry of Health, Labor and Welfare has approved XELJANZ for the treatment of adults with rheumatoid arthritis who have had an inadequate response to existing therapies. XELJANZ may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying antirheumatic drug, such as methotrexate. The recommended dose of XELJANZ is 5 mg twice daily. XELJANZ will be commercially available in Japan after the National Health Insurance listing and will be co-promoted in Japan by Pfizer and Takeda Pharmaceutical Company Limited. Pfizer and Takeda also currently co-promote the RA drug Enbrel in Japan.